Excelsior Medical Co., Ltd. (4104.TW)
TWD 86.6
(-0.46%)
TWD 86.6
(-0.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.44 Billion TWD | 78.55% |
| 2022 | 808.45 Million TWD | 6.04% |
| 2021 | 762.39 Million TWD | 6.93% |
| 2020 | 712.97 Million TWD | -51.47% |
| 2019 | 1.46 Billion TWD | 32.08% |
| 2018 | 1.11 Billion TWD | -24.49% |
| 2017 | 1.47 Billion TWD | 19.93% |
| 2016 | 1.22 Billion TWD | -14.46% |
| 2015 | 1.43 Billion TWD | -15.74% |
| 2014 | 1.7 Billion TWD | 8.06% |
| 2013 | 1.57 Billion TWD | -12.61% |
| 2012 | 1.8 Billion TWD | -14.79% |
| 2011 | 2.11 Billion TWD | 80.07% |
| 2010 | 1.17 Billion TWD | 78.17% |
| 2009 | 660.03 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.05 Billion TWD | -26.67% |
| 2024 Q2 | 1.49 Billion TWD | 41.26% |
| 2023 Q4 | 1.44 Billion TWD | 14.7% |
| 2023 FY | 1.44 Billion TWD | 78.55% |
| 2023 Q1 | 805.99 Million TWD | -0.3% |
| 2023 Q2 | 722.08 Million TWD | -10.41% |
| 2023 Q3 | 1.25 Billion TWD | 74.29% |
| 2022 Q4 | 808.45 Million TWD | -13.32% |
| 2022 FY | 808.45 Million TWD | 6.04% |
| 2022 Q2 | 714.92 Million TWD | 1.3% |
| 2022 Q1 | 705.76 Million TWD | -7.43% |
| 2022 Q3 | 932.67 Million TWD | 30.46% |
| 2021 FY | 762.39 Million TWD | 6.93% |
| 2021 Q3 | 806.62 Million TWD | 27.52% |
| 2021 Q4 | 762.39 Million TWD | -5.48% |
| 2021 Q1 | 656.88 Million TWD | -7.87% |
| 2021 Q2 | 632.55 Million TWD | -3.7% |
| 2020 Q3 | 707.74 Million TWD | 11.19% |
| 2020 Q4 | 712.97 Million TWD | 0.74% |
| 2020 FY | 712.97 Million TWD | -51.47% |
| 2020 Q2 | 636.53 Million TWD | -55.35% |
| 2020 Q1 | 1.42 Billion TWD | -2.96% |
| 2019 Q3 | 1.95 Billion TWD | 45.22% |
| 2019 Q2 | 1.34 Billion TWD | -2.62% |
| 2019 Q1 | 1.38 Billion TWD | 24.53% |
| 2019 Q4 | 1.46 Billion TWD | -24.99% |
| 2019 FY | 1.46 Billion TWD | 32.08% |
| 2018 Q2 | 1.24 Billion TWD | 24.12% |
| 2018 Q4 | 1.11 Billion TWD | -24.92% |
| 2018 FY | 1.11 Billion TWD | -24.49% |
| 2018 Q1 | 1 Billion TWD | -32.01% |
| 2018 Q3 | 1.48 Billion TWD | 19.18% |
| 2017 Q3 | 1.5 Billion TWD | -2.14% |
| 2017 FY | 1.47 Billion TWD | 19.93% |
| 2017 Q4 | 1.47 Billion TWD | -2.35% |
| 2017 Q2 | 1.54 Billion TWD | -11.21% |
| 2017 Q1 | 1.73 Billion TWD | 41.35% |
| 2016 Q2 | 1.57 Billion TWD | 5.87% |
| 2016 Q1 | 1.48 Billion TWD | 3.32% |
| 2016 FY | 1.22 Billion TWD | -14.46% |
| 2016 Q4 | 1.22 Billion TWD | -10.95% |
| 2016 Q3 | 1.37 Billion TWD | -12.18% |
| 2015 FY | 1.43 Billion TWD | -15.74% |
| 2015 Q1 | 1.55 Billion TWD | -8.82% |
| 2015 Q4 | 1.43 Billion TWD | -7.67% |
| 2015 Q2 | 1.8 Billion TWD | 15.87% |
| 2015 Q3 | 1.55 Billion TWD | -13.62% |
| 2014 FY | 1.7 Billion TWD | 8.06% |
| 2014 Q2 | 1.49 Billion TWD | -7.62% |
| 2014 Q3 | 1.27 Billion TWD | -15.04% |
| 2014 Q4 | 1.7 Billion TWD | 33.96% |
| 2014 Q1 | 1.62 Billion TWD | 2.78% |
| 2013 Q3 | 2.1 Billion TWD | 4.41% |
| 2013 Q4 | 1.57 Billion TWD | -24.98% |
| 2013 FY | 1.57 Billion TWD | -12.61% |
| 2013 Q2 | 2.01 Billion TWD | 29.74% |
| 2013 Q1 | 1.55 Billion TWD | -14.0% |
| 2012 Q1 | 2.36 Billion TWD | 11.45% |
| 2012 FY | 1.8 Billion TWD | -14.79% |
| 2012 Q4 | 1.8 Billion TWD | -0.31% |
| 2012 Q3 | 1.81 Billion TWD | -9.17% |
| 2012 Q2 | 1.99 Billion TWD | -15.56% |
| 2011 Q3 | 1.93 Billion TWD | 43.94% |
| 2011 Q1 | 1.32 Billion TWD | 12.9% |
| 2011 Q2 | 1.34 Billion TWD | 1.0% |
| 2011 Q4 | 2.11 Billion TWD | 9.72% |
| 2011 FY | 2.11 Billion TWD | 80.07% |
| 2010 Q4 | 1.17 Billion TWD | 0.0% |
| 2010 FY | 1.17 Billion TWD | 78.17% |
| 2009 FY | 660.03 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Apex Medical Corp. | 364.55 Million TWD | -295.96% |
| OK Biotech Co., Ltd. | 332.97 Million TWD | -333.51% |
| Applied BioCode Corporation | 34.43 Million TWD | -4092.382% |